Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A G Dalgleish

Showing results (141-150 of 222) with videos related to

Pageof 23
Sort By:
Clinical and Experimental Immunology|December 22, 1999
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitroL La Maestra, A Zaninoni, J B Marriott, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentationT R Evans, J L Mansi, D H Bevan, et al.
Clinical and Experimental Immunology|October 9, 1998
Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type responseG P Rizzardi, J B Marriott, S Cookson, et al.
Clinical and Experimental Immunology|September 26, 2002
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cellsJ B Marriott, I A Clarke, K Dredge, et al.
AIDS (London, England)|May 1, 1987
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complexC F Farthing, A G Dalgleish, A Clark, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant diseaseK J O'Byrne, A G Dalgleish, M J Browning, et al.
The Lancet. Oncology|March 21, 2002
Angiogenesis as a biomarker and target in cancer chemopreventionR A Sharma, A L Harris, A G Dalgleish, et al.
The British Journal of Dermatology|July 12, 2008
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanomaD S Green, A G Dalgleish, N Belonwu, et al.
AIDS (London, England)|February 1, 1990
Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive peopleD Wilks, L C Walker, J A Habeshaw, et al.
British Journal of Urology|January 12, 1999
Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancerD Hrouda, B E Souberbielle, J Kayaga, et al.
Pageof 23

Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
Clinical and Experimental Immunology|December 22, 1999
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitroL La Maestra, A Zaninoni, J B Marriott, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentationT R Evans, J L Mansi, D H Bevan, et al.
Clinical and Experimental Immunology|October 9, 1998
Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type responseG P Rizzardi, J B Marriott, S Cookson, et al.
Clinical and Experimental Immunology|September 26, 2002
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cellsJ B Marriott, I A Clarke, K Dredge, et al.
AIDS (London, England)|May 1, 1987
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complexC F Farthing, A G Dalgleish, A Clark, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant diseaseK J O'Byrne, A G Dalgleish, M J Browning, et al.
The Lancet. Oncology|March 21, 2002
Angiogenesis as a biomarker and target in cancer chemopreventionR A Sharma, A L Harris, A G Dalgleish, et al.
The British Journal of Dermatology|July 12, 2008
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanomaD S Green, A G Dalgleish, N Belonwu, et al.
AIDS (London, England)|February 1, 1990
Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive peopleD Wilks, L C Walker, J A Habeshaw, et al.
British Journal of Urology|January 12, 1999
Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancerD Hrouda, B E Souberbielle, J Kayaga, et al.
Pageof 23